IMA402 (TCER®)
PRAME-positive solid tumors
Phase 1/2Candidate Selected
Key Facts
About Immatics
Immatics is a clinical-stage biotech company with a mission to develop novel, targeted immunotherapies for solid tumors. Its core achievement is building a dominant, multi-modality pipeline targeting PRAME, an antigen expressed in over 50 cancer types, using its proprietary XPRESIDENT® and XCEPTOR® discovery platforms. The company's strategy is to advance its lead TCR-T cell therapy (IMA203CD8) and bispecific TCR candidates through clinical development, leveraging its transatlantic operational footprint and strategic partnerships to bring precision oncology treatments to a broad patient population.
View full company profileTherapeutic Areas
Other PRAME-positive solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| IMA203 | Immatics Biotechnologies | Phase 1/2 |
| IMA203CD8 | Immatics Biotechnologies | Phase 1/2 |
| IMA402 | Immatics Biotechnologies | Phase 1/2 |
| TK-6302 | T-Knife Therapeutics | Pre-clinical |
| Anzu-cel (IMA203C) | Immatics | Phase 1 |